Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by ...

AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 recruitment has begun following positive data from Cohort 1 Aethlon Medical (NASDAQ:AEMD) announced FY 2Q (quarter ended September 30, 2025) results ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

So, one of the areas of highest unmet needs in triple-negative breast cancer is the recurrence post-chemo and immunotherapy ...